Sox2 is involved in paclitaxel resistance of the prostate cancer cell line PC-3 via the PI3K/Akt pathway

• Published in: Molecular medicine reports Vol. 10; no. 6; pp. 3169 - 3176
• Main Authors: LI, DONG, ZHAO, LI-NAN, ZHENG, XIU-LAN, LIN, PING, LIN, FENG, LI, YUE, ZOU, HAI-FENG, CUI, RONG-JUN, CHEN, HUI, YU, XIAO-GUANG
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.12.2014; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: 1-Phosphatidylinositol 3-kinase; AKT protein; Androgens; Apoptosis; Apoptosis - drug effects; Apoptosis - genetics; Carcinogenesis; Cell cycle; Cell Line, Tumor; Cell proliferation; Cell Proliferation - drug effects; Cell Proliferation - genetics; Cellular signal transduction; Chemotherapy; Cyclin E; Cyclin E - genetics; Cyclin-dependent kinases; Drug resistance; Drug Resistance, Neoplasm - genetics; Drug therapy; G1 Phase - drug effects; G1 Phase - genetics; Genetic aspects; Health aspects; Humans; Inhibitor of Apoptosis Proteins - genetics; Kinases; Male; Overexpression; Paclitaxel; Paclitaxel - pharmacology; Phase transitions; Phosphatidylinositol 3-Kinases - genetics; phosphoinositide 3-kinase/Akt pathway; Physiological aspects; Prostate cancer; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - genetics; Proto-Oncogene Proteins c-akt - genetics; Risk factors; S phase; S Phase - drug effects; S Phase - genetics; Signal transduction; Signal Transduction - drug effects; Signal Transduction - genetics; Sox2; SOXB1 Transcription Factors - genetics; Stem cells; Survivin; China; United States > US
• ISSN: 1791-2997; 1791-3004; 1791-3004
• DOI: 10.3892/mmr.2014.2630

Prostate cancer is the most commonly diagnosed type of cancer and the second leading cause of cancer-associated mortality in males. The efficacy of prostate cancer chemotherapy is frequently impaired by drug resistance; however, the underlying mechanisms of this resistance remain elusive. Sex determining region Y-box 2 (Sox2) is of vital importance in the regulation of stem cell proliferation and carcinogenesis. In the present study, using MTT, clone formation, cell cycle and apoptosis assays, over-expression of Sox2 was demonstrated to enhance the paclitaxel (Pac) resistance of the PC-3 prostate cancer cell line, promoting cell proliferation and exhibiting an anti-apoptotic effect. Western blot analysis revealed that the phosphoinositide 3-kinase/Akt signaling pathway was activated in cells overexpressing Sox2, and by targeting cyclin E and survivin, Sox2 promoted G1/S phase transition and prevented apoptosis under Pac treatment. The present study provided an understanding of Pac resistance in prostate cancer and may indicate novel therapeutic methods for chemoresistant prostate cancer.